Campbell; Ian Baxter

Patent Applications and Registrations

Patent applications and USPTO patent grants for Campbell; Ian Baxter.The latest application filed is for "naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases".

Company Profile

2.11.9

Campbell; Ian Baxter - Stevenage GB
Campbell; Ian Baxter - Hertfordshire GB
Campbell; Ian Baxter - Broom GB
Campbell; Ian Baxter - Biggleswade GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases Grant 10,513,517 - Anderson , et al. Dec	2019-12-24
Naphthyridine Derivatives As Alpha V Beta 6 Integrin Antagonists For The Treatment Of E.g. Fibrotic Diseases App 20190048005 - ANDERSON; Niall Andrew ; et al.	2019-02-14
Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases Grant 10,144,733 - Anderson , et al. De	2018-12-04
Naphthyridine Derivatives As Alpha V Beta 6 Integrin Antagonists For The Treatment Of E.g. Fibrotic Diseases App 20170291899 - ANDERSON; Niall Andrew ; et al.	2017-10-12
Bicyclic imidazole as DP1 receptor antagonists Grant 8,399,444 - Campbell , et al. March 19, 2	2013-03-19
Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions App 20120277279 - BARNETT; Heather Anne ; et al.	2012-11-01
Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions Grant 8,247,377 - Barnett , et al. August 21, 2	2012-08-21
Novel Compounds App 20110245310 - Campbell; Ian Baxter ; et al.	2011-10-06
Novel Compounds App 20100234441 - Barnett; Heather Anne ; et al.	2010-09-16
Pyrazole Derivatives As Non-steroidal Glucocorticoid Receptor Ligands App 20100035926 - Campbell; Ian Baxter ; et al.	2010-02-11
Pyrazolopyridine derivatives as selective cox-2 inhibitors Grant 7,223,772 - Campbell , et al. May 29, 2	2007-05-29
2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors App 20050113377 - Beswick, Paul John ; et al.	2005-05-26
2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors Grant 6,861,429 - Beswick , et al. March 1, 2	2005-03-01
2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors Grant 6,831,097 - Beswick , et al. December 14, 2	2004-12-14
2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibirors App 20030040517 - Beswick, Paul John ; et al.	2003-02-27
2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors App 20030008872 - Beswick, Paul John ; et al.	2003-01-09
Pyrazolopyridines Grant 6,498,166 - Campbell , et al. December 24, 2	2002-12-24
2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors Grant 6,451,794 - Beswick , et al. September 17, 2	2002-09-17
Bipyridine manganese complexes Grant 6,177,419 - Campbell , et al. January 23, 2	2001-01-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.